BioStem Technologies Reports Record Revenue of $11.5M for Q4 2023

New York, April 04, 2024 - PRISM MarketView - Leading regenerative medicine company, BioStem Technologies (OTC: BSEM) has reported record revenues for the fourth quarter of 2023, reaching $11.5 million, a 1,355% increase year-over-year. The company achieved gross profit of $10.9 million, adjusted EBITDA income of $1.67 million in the fourth quarter of 2023, and net revenue of $16.7 million, an increase of 143% year-over-year.

The company achieved a number of key milestones during the year, including the successful acquisition of Auxocell Laboratories, a leading solid tissue processing equipment manufacturer, and entering a partnership with NovaBay Pharmaceuticals for the commercialization of the Avenova Allograft™ optic allograft.

Mr. Matuszewski said the impressive growth was driven by the successful commercial launch of AmnioWrap2, the company’s innovative placental-derived allograft product designed to address a broad spectrum of wound applications, in partnership with Venture Medical.

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2®, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information, please visit: http://www.biostemtechnologies.com

BioStem Technologies (OTC: BSEM) is featured on PRISM Emerging MedDevices Index 

Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.

PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.

PRISM MarketView
info@prismmarketview.com
646-863-6341